Sei Investments Co. Trims Stock Position in GeneDx Holdings Corp. $WGS

Sei Investments Co. trimmed its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 52.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,660 shares of the company’s stock after selling 19,209 shares during the quarter. Sei Investments Co. owned about 0.06% of GeneDx worth $1,134,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Sumitomo Mitsui Trust Group Inc. raised its holdings in GeneDx by 30.6% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 381,725 shares of the company’s stock valued at $49,647,000 after buying an additional 89,470 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of GeneDx by 4.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after acquiring an additional 52,322 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of GeneDx by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock valued at $154,650,000 after acquiring an additional 18,647 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of GeneDx by 60.4% in the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock valued at $142,154,000 after acquiring an additional 411,607 shares in the last quarter. Finally, Renaissance Group LLC bought a new position in shares of GeneDx in the 4th quarter valued at approximately $7,167,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Stock Performance

WGS opened at $82.39 on Thursday. The firm has a market capitalization of $2.46 billion, a P/E ratio of -22.63 and a beta of 1.92. The stock’s 50 day moving average price is $64.51 and its two-hundred day moving average price is $67.87. The company has a quick ratio of 3.06, a current ratio of 3.30 and a debt-to-equity ratio of 0.40. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.20. GeneDx had a positive return on equity of 4.12% and a negative net margin of 23.41%.The company had revenue of $114.44 million for the quarter, compared to the consensus estimate of $111.01 million. During the same period in the previous year, the business posted $0.36 EPS. On average, equities analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on WGS. Craig Hallum reaffirmed a “buy” rating and set a $85.00 target price on shares of GeneDx in a research report on Tuesday, May 5th. Wall Street Zen raised shares of GeneDx from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research upgraded shares of GeneDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. BTIG Research reaffirmed a “buy” rating and set a $90.00 price objective on shares of GeneDx in a report on Tuesday, August 4th. Finally, Guggenheim reiterated a “buy” rating and issued a $74.00 target price (up from $70.00) on shares of GeneDx in a research note on Monday, June 29th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and a consensus target price of $89.57.

Insider Activity at GeneDx

In related news, Director Casdin Capital, Llc bought 185,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was purchased at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the purchase, the director directly owned 3,367,164 shares in the company, valued at $143,441,186.40. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Katherine Stueland sold 10,501 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total transaction of $638,145.77. Following the completion of the sale, the chief executive officer directly owned 104,372 shares of the company’s stock, valued at approximately $6,342,686.44. This trade represents a 9.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders acquired 746,273 shares of company stock worth $34,370,132 and sold 19,135 shares worth $1,128,499. 25.17% of the stock is owned by company insiders.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.